Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ761 and Olaparib in Refractory Advanced Solid Tumors
NCT03575078Phase 1Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ARQ761 in solid tumor and lymphoma, sponsored by UT Southwestern Medical Center. Primary endpoint: Maximum Tolerated Dose. Planned start Jun 2018; status: withdrawn.
02
Drugs
ARQ761
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03575078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575078.